Semaglutide, a long-acting GLP-1 agonist, exhibited a sustained weight decrease of approximately 15% of body weight in clinical studies, whereas tirzepatide, a combination GIP/GLP-1 agonist, attained a weight loss of up to 22.5% in the SURMOUNT trials [36,37]
Monday Poster Session Category: Small Intestine P4045 - Comparative Risk of Small Intestinal Bacterial Overgrowth (SIBO) Among Patients Using GLP-1 Receptor Agonists: A Real-World Analysis Using TriNetX Monday, October 27, 2025 10:30 AM - 4:00 PM PDT Location: Exhibit Hall Has Audio Presenting Author(s) Lina AlQirem, MD 1 , Suria Devarapalli, DO 1 , Adalberto Guzman, MD 2 , Murad Qirem, MD 3 , Meer A
Insulin resistance causes fatty liver, and fatty liver worsens insulin resistance
The platform eliminates the most common barriers to healthcare with asynchronous telehealth visits that empower patients to get care at any time without appointments, travel, or waiting rooms